World Respiratory Drug Market Expected to Soar Past $44 Billion by 2010

New York, November 10, 2006 — As the incidence of respiratory illness skyrockets around the globe, the use of prescription respiratory drugs is expected to continue mushrooming into an exponentially lucrative market, with 2010 sales expected to surpass $44 billion.

According to the latest market research, The World Market for Prescription Respiratory Drugs, a study released today from Kalorama Information, 2005 revenues for therapies addressing the wide range of respiratory diseases reached more than $32 billion, having grown at a compound annual rate of 11.1% from 2000’s $19 billion. New delivery methods, improved product performance, and an increasing incidence combined with an aging population have fueled the market.

While there have been setbacks, such as patent losses, increasing drug resistance issues, and the burden of mandatory post-approval drug studies, among others, the potential for new biologics and orphan drugs are keeping the focus of the industry on championing the unmet needs of respiratory sufferers.

“Increased understanding of respiratory disease processes coupled with advancements in drug delivery technology are making it possible for those with even the most acute respiratory ailments to find relief and improve the quality and longevity of their lives,” notes Mary Anne Crandall, the report’s author. “For example, scientists have discovered a drug that makes damaged lungs regrow – raising hopes of a cure for emphysema. It opens up a new field of biology which could potentially be applied to other organs that do not repair themselves naturally.”

The study examines the global market for anti-inflammatories and inhaled corticosteroids; mast stabilizers, leukotriene modifiers, and other biologics; antihistamines, decongestants, and antitussives; brochodilators; lung fluid replacement and mucokinetic agents; and other drugs used to treat and manage symptoms in a wide range of respiratory illnesses.

The World Market for Prescription Respiratory Drugs also includes research and development pipelines, in-depth company profiles, epidemiology of the relevant conditions, geographic revenue breakdowns, and revenues and market shares of the leading suppliers. It can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1190854.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240.747.3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.